$7.14
4.16%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US21833P1030
Symbol
CRBP

Corbus Pharmaceuticals Holdings Inc Target price 2026 - Analyst rating & recommendation

Corbus Pharmaceuticals Holdings Inc Classifications & Recommendation

Buy
94%
Hold
6%

Corbus Pharmaceuticals Holdings Inc Price Target

Target Price $35.70
Price $7.14
Potential
Number of Estimates 11
11 Analysts have issued a price target Corbus Pharmaceuticals Holdings Inc 2027 . The average Corbus Pharmaceuticals Holdings Inc target price is $35.70. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 15 Analysts recommend Corbus Pharmaceuticals Holdings Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Corbus Pharmaceuticals Holdings Inc stock has an average upside potential 2027 of . Most analysts recommend the Corbus Pharmaceuticals Holdings Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
P/E negative
EV/Sales 20.51

12 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast for earnings per share. The average Corbus Pharmaceuticals Holdings Inc EPS is

$-5.32
unlock
. This is
1.33% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-4.26 18.86%
unlock
, the lowest is
$-6.06 15.43%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2027
$-5.58 4.89%
unlock
2028
$-5.84 4.66%
unlock
2029
$-4.65 20.38%
unlock
2030
$0.49 110.54%
unlock
2031
$6.62 1,251.02%
unlock
2032
$11.88 79.46%
unlock
2033
$11.80 0.67%
unlock

P/E ratio

Current -1.36 44.06%
2026
-1.40 1.34%
unlock
2027
-1.34 4.29%
unlock
2028
-1.28 4.48%
unlock
2029
-1.60 25.00%
unlock
2030
15.08 1,042.50%
unlock
2031
1.13 92.51%
unlock
2032
0.63 44.25%
unlock
2033
0.63 0.00%
unlock

Current Corbus Pharmaceuticals Holdings Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 14 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Aug 07 2026
Oppenheimer
Locked
➜
Locked
Locked Aug 07 2026
Mizuho
Locked
➜
Locked
Locked Jun 23 2026
Oppenheimer
Locked
➜
Locked
Locked Jun 17 2026
Wedbush
Locked
➜
Locked
Locked May 27 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked May 26 2026
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 14 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Aug 07 2026
Locked
Oppenheimer:
Locked
➜
Locked
Aug 07 2026
Locked
Mizuho:
Locked
➜
Locked
Jun 23 2026
Locked
Oppenheimer:
Locked
➜
Locked
Jun 17 2026
Locked
Wedbush:
Locked
➜
Locked
May 27 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
May 26 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today